Hookipa Pharma (HOOK) announced that the first person has been dosed in a Phase 1b clinical trial of HB-500, an investigational therapeutic vaccine for the treatment of HIV. As a result, Hookipa achieved a $5M non-dilutive milestone payment under its collaboration and license agreement with Gilead (GILD). The Phase 1b clinical trial will evaluate the safety and tolerability, reactogenicity, and immunogenicity to repeated doses of HB-500 in participants with HIV on suppressive antiretroviral treatment. The Phase 1b design comprises two dose escalation cohorts that will be randomized to receive HB-500 or placebo. The first participant was dosed on July 1 and enrollment is ongoing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOOK:
- HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
- Hookipa Pharma price target raised to $6 from $5 at H.C. Wainwright
- Hookipa Pharma’s HB-200 Shows Promise in Phase 2 Cancer Trial
- Hookipa Pharma to host conference call
- HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
Questions or Comments about the article? Write to editor@tipranks.com